

## **COMMON CANCERS SHARE FAMILIAL SUSCEPTIBILITY: IMPLICATIONS FOR CANCER GENETICS AND COUNSELING**

*\*Correspondence to:* Hongyao Yu, Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany. Tel: +49-6221-421800; Fax: +49-6221-421810; E-Mail: h.yu@dkfz.de

Hongyao Yu <sup>1</sup>, Christoph Frank <sup>1</sup>, Jan Sundquist <sup>2,3</sup>, Akseli Hemminki<sup>4,5</sup> and Kari Hemminki <sup>1,2</sup>

<sup>1</sup>Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), 69120 Heidelberg, Germany;

<sup>2</sup>Center for Primary Health Care Research, Lund University, Malmö, Sweden;

<sup>3</sup>Stanford Prevention Research Center, Stanford University School of Medicine, California,USA;

<sup>4</sup>Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Finland

<sup>5</sup> Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

Running title: Discordant familial cancer.

*Key words: cancer susceptibility, discordant familial cancer, familial risk, population database.*

Word count: 2244

## **ABSTRACT**

**Background:** It has been proposed that cancer is more common in some families than in others, but the hypothesis lacks population level support. We use a novel approach by studying any cancers in large 3-generation families and thus are able to find risks even though penetrance is low.

**Methods:** Individuals in the nation-wide Swedish Family-Cancer Database were organized in 3 generations and the relative risk (RR) of cancer was calculated to the persons in the third generation by the numbers of cancer patients in generations 1, 2 and 3.

**Results:** The RRs for any cancer in generation 3 increased by numbers of affected relatives, reaching 1.61 when at least 7 relatives were diagnosed. The median patient had 2 affected relatives, and 7.0% had 5 or more affected relatives with an RR of 1.46, which translated to an absolute risk of 21.5% compared to 14.7% in population by age 65 years. For prostate cancer, the RR was 2.85 with 4 or more affected family members with any cancer, and it increased to 14.42 with 4 or more concordant cancers in family members. RRs for prostate cancer were approximate equal (2.70 vs 2.85) if a man had 1 relative with prostate cancer or 4 or more relatives diagnosed with any cancer.

**Conclusions:** A strong family history of cancer, regardless of tumor type, increases cancer risk of family members and calls for mechanistic explanations. Our data provide tools for counseling of cancer patients with both low and high familiar risks.

## INTRODUCTION

The absence of correlation of risk of most cancers between spouses, particularly those not related to tobacco smoking, suggests that familial cancers are mainly due to genetic causes [1]. However, the known genes explain a small proportion of the familial clustering and, consistently, a recent analysis of genome-wide association studies (GWASs) on 13 cancers could explain no more than 15 to 53% of the empirical familial risk [2, 3]. A further question is the sharing of familial risks between cancer sites. Data on many known cancer syndromes show pleiotropic effects on multiple sites. For example, hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome), initially found in colorectal cancer families, was later shown to be associated with a high risk of endometrial cancers and a somewhat lower risk of at least half a dozen other cancers [4]. Similarly, BRCA1 and BRCA2 which were identified in breast and ovarian cancer pedigrees, are now known to predispose to at least five other tumors [5]. A review of Rahman on cancer predisposing genes listed 114 genes and only 39% were associated with cancer at a single site [6]. Even this figure is likely to be too high because the initial studies focus on a single cancer type.

Thus, despite an intense research effort in the past two decades, cancer predisposing genes seem to account for a small proportion of familial cancer, and the above GWAS analysis concluded that “most pairs of cancers...are unlikely to have strong genetic correlations” [3]. Population-based family studies from Utah, Iceland and Sweden have reported results on different (i.e., discordant) sites, and the Utah and the Icelandic data covered more than 2 generations [7-10]. In the Utah dataset, associations were estimated for 36 different cancer sites. Prostate cancer had most interactions with other cancer sites, and its relative risks were increased in the first-, second-, and third-degree relatives when probands diagnosed with 11 different cancer sites [7]. According to the Icelandic data, 20 discordant cancer pairs were significant of 351 pairs tested and the relative

risks ranged from 1.1 to 1.5 among second degree relatives [9]. Based on the Swedish study on discordant cancers, we concluded our large study on 33 cancer sites: “Within the present sample size limits, we found no evidence of an overall susceptibility to cancer” [10].

The issue of a general susceptibility to cancer does not appear to be settled because cancer syndromes often manifest multiple and diverse cancers while population-level family studies show far lower risks, if any, in discordant compared to concordant familial cancers. A limitation in published family studies has been a focus on pairs of selected cancers (A and B). Such a design would perform well if a genetic factor causes a reasonable risk (reasonably high penetrance) in cancers A and B but the statistical power would be low if a gene or a set of genes cause a lower risk (low penetrance) of many cancers. We present here a novel approach of analyzing cancers in 3 generations and considering risks for any cancer and for the most common individual cancers. By combining data on first, second and third degree relatives we could identify families with large numbers of affected individuals. The data are relevant to genetic counseling, which understandably focuses on high risk syndromes and families. More broadly, our findings are useful in the general oncology practice, because they help physicians answer very common questions relating to the familial risks “caused by” malignancies found in the patients’ extended families.

## **PATIENT AND METHODS**

The Swedish Family-Cancer Database (FCD) was used to estimate familial cancer risks. It was formed by merging data from the Multigeneration Register, the Swedish Cancer Registry and several other databases [11-13]. The individual linkages in the databases were based on the unique national identification number. The latest update of the FCD contains information until 2012, including 15.7 million individuals and 1.8 million medically verified cancer cases. The

FCD is composed of children born from 1932 onwards and their biological parents. The available offspring-mother-father triplets were used to create pedigrees comprising of first-degree relatives (parents and siblings), second-degree relatives (grandparents, uncles and aunts) and third-degree relatives (cousins). In the present study, individuals born before 1932 for which no parental linkage was available were considered as the first generation. Individuals born between 1932 and 1951 were defined as the second generation. Offspring of the second generation were defined as the third generation. A total of 1,846,840 third generation individuals were enrolled into the study as index individuals who were used for calculating the cancer risks and the number of their first-degree, second-degree and third-degree relatives affected with cancers was regarded as probands who was used to define the different family histories.

Among the index individuals 41,106 cancers were diagnosed. A 4-digit diagnostic code, the 7th version of International Classification of Disease (ICD-7), was used to identify the cancer site. To estimate individual cancer risks for any cancer in the family, the 33 most common cancers were taken into consideration, including the upper aerodigestive tract, esophagus, stomach, small intestine, colorectum, anus, liver, pancreas, nose, lung, breast, cervix, endometrium, uterus, ovary, other female genital, prostate, testis, other male genital, kidney, urinary bladder, melanoma, skin, eye, nervous system, thyroid gland, other endocrine glands, bone, connective tissue and hematopoietic tissue (non-Hodgkin's lymphoma, Hodgkin's disease, myeloma and leukemia). In addition, tobacco related cancers were defined as lung, upper aerodigestive tract, kidney, and bladder cancers. Due to the small case numbers, the latter three were merged into one group termed 'other tobacco related cancers'. For the most common cancers of the breast, prostate, colorectum and lung, risks for concordant cancers in the family were also investigated. Since breast cancer is sex-specific, only female cases among the index individuals were taken into account.

Based on the index individuals, person-years and cases were calculated stratifying for different family histories (i.e., numbers of relatives with cancer) and potential confounders such as sex, age, calendar period, residential area, and socioeconomic status. Considering these stratification variables as covariates, a Poisson regression model was employed to estimate familial risks. Thereby, relative risks (RRs) in terms of incidence rate ratios and their 95% confidence intervals (CIs) were calculated for different family histories [14]. Familial risks were found to be significantly increased or decreased, respectively, if the 95% CI did not include 1.00. Trend tests were performed to assess whether RRs increased by the number of the affected relatives. P-values less than 0.05 were considered statistically significant.

All statistical analyses were performed using SAS software version 9.3. The Lund University regional ethics committee approved the study.

## **RESULTS**

The birth years of cancer patients identified in the 3 generations probands under study are shown in Fig. 1. The probands among 3 generations had 468,549, 367,642 and 48,730 cancers, respectively. The risk was calculated to the third generation depending on the numbers and types of cancers in the proband generations; the birth years of cancer patients in the 3 generations show maximal births in years 1920, 1943 and 1964, respectively.

Table 1 shows the distribution of family sizes and cancer cases among the third generation, with a minimum of less than 5 (with missing parental or grandparental information) and a maximum of more than 60. The proportion of cancer patients among the 1,846,840 individuals in the third generation appears not to depend on the family size.

Table 1 Family size and cancer cases distribution among the third generation

	Family size													Total
	<=5	6-10	11-15	16-20	21-25	26-30	31-35	36-40	41-45	46-50	51-55	56-60	>60	
Cancer cases	5,430	9,439	10,150	7,350	4,211	2,202	1,150	579	279	149	86	32	49	41,106
index individuals	254,706	385,914	451,620	339,970	198,819	104,858	53,980	27,741	14,070	7,238	3,927	1,975	2,022	1,846,840
Percent	2.13%	2.45%	2.25%	2.16%	2.12%	2.10%	2.13%	2.09%	1.98%	2.06%	2.19%	1.62%	2.42%	2.23%

Cancer risks in the third generation are shown in Table 2 by the number of cancer patients in generations 1, 2 and 3. Risks were compared to those without relatives with cancer. For men the highest RR was 1.46 when 7 or more relatives were diagnosed with cancer; for women the highest RR was 1.72 when 7 or more relatives were diagnosed. In data on combined sexes, the RRs reached 1.61 when at least 7 relatives were diagnosed. The RRs increased by numbers of affected relatives (all trend test p-values < 0.0001). The median patient in the third generation had 2 affected relatives and 7.0% had 5 or more affected relatives.

Table 2 Familial risks for any cancer among the third generation

Cancer cases in the family	Male			Female			Total		
	N <sup>1</sup>	RR <sup>2</sup>	95%CI <sup>3</sup>	N	RR	95%CI	N	RR	95%CI
0	2605	ref <sup>4,5</sup>	--	3721	ref <sup>5</sup>	--	6326	ref <sup>5</sup>	--
1	4334	<b>1.07</b>	(1.01-1.13)	6362	<b>1.10</b>	(1.04-1.15)	10696	<b>1.08</b>	(1.04-1.13)
2	4151	<b>1.11</b>	(1.05-1.18)	6172	<b>1.17</b>	(1.11-1.23)	10323	<b>1.14</b>	(1.10-1.19)
3	2793	<b>1.14</b>	(1.08-1.21)	4282	<b>1.23</b>	(1.16-1.30)	7075	<b>1.19</b>	(1.14-1.24)
4	1578	<b>1.28</b>	(1.19-1.37)	2247	<b>1.27</b>	(1.19-1.36)	3825	<b>1.28</b>	(1.21-1.34)
5	725	<b>1.36</b>	(1.24-1.49)	976	<b>1.29</b>	(1.19-1.41)	1701	<b>1.32</b>	(1.24-1.41)
6	290	<b>1.44</b>	(1.26-1.65)	424	<b>1.44</b>	(1.27-1.63)	714	<b>1.44</b>	(1.31-1.58)
7+	166	<b>1.46</b>	(1.23-1.74)	280	<b>1.72</b>	(1.48-2.00)	446	<b>1.61</b>	(1.43-1.82)

1: N=Number of cancer cases among the index individuals;

2: RR=Relative risk;

3: CI=Confidence interval;

4: ref=Reference;

5: Trend test p-value < **0.0001**.

In Table 3 we show results for specific cancers in four ways of defining proband cancers, on top by considering any cancer and in the bottom by considered only concordant cancer. In addition any cancer excluding concordant cancer and any cancer excluding concordant cancer and cancer syndrome were also taken into consideration.

For lung cancer the RRs were significantly increased when relatives were diagnosed with concordant cancer only (trend test p-value < 0.0001). For colorectal, prostate and breast cancers, most comparisons were significant and all the trend tests were statistically significant; For prostate cancer, when probands had any cancer, the RR increased to 2.85 with 4 or more affected family members, and it increased to 14.42 with 4 or more concordant cancers in family members. For breast cancer, the RR increased to 1.48 with 4 or more affected family members with any cancer, and it increased to 3.77 with 4 concordant cancers in family members.

Table 3 Familial risks for colorectal, lung, prostate and breast cancers among the third generation for different family histories

Cancer cases in the family	Colorectal cancer				Lung cancer			Prostate cancer			Breast cancer		
	N <sup>1</sup>	RR <sup>2</sup>	95%CI <sup>3</sup>		N	RR	95%CI	N	RR	95%CI	N	RR	95%CI
0	326	ref <sup>4</sup>	--		114	ref	--	85	ref	--	1063	ref	--
Any cancer	1	552	1.09	(0.92-1.29)	195	1.11	(0.85-1.44)	176	<b>1.38</b>	(1.02-1.86)	1801	1.09	(0.99-1.19)
	2	572	<b>1.25</b>	(1.05-1.47)	182	1.19	(0.91-1.55)	183	<b>1.70</b>	(1.26-2.28)	1785	<b>1.20</b>	(1.09-1.31)
	3	372	<b>1.23</b>	(1.03-1.48)	117	1.18	(0.88-1.59)	107	<b>1.62</b>	(1.17-2.25)	1269	<b>1.29</b>	(1.17-1.43)
	4+	373	<b>1.44</b>	(1.20-1.73)	111	1.30	(0.96-1.75)	164	<b>2.85</b>	(2.11-3.86)	1248	<b>1.48</b>	(1.33-1.63)
P-value for trend test			<b>&lt; 0.0001</b>			0.08				<b>&lt; 0.0001</b>			<b>&lt; 0.0001</b>
Any cancer (excluding concordant cancer) <sup>5</sup>	0	326	ref	--	114	ref	--	85	ref	--	1063	ref	--
	1	619	1.12	(0.95-1.33)	203	1.10	(0.84-1.42)	233	<b>1.66</b>	(1.27-2.17)	2094	<b>1.14</b>	(1.05-1.25)
	2	547	<b>1.21</b>	(1.02-1.44)	187	1.24	(0.95-1.61)	150	<b>1.46</b>	(1.09-1.94)	1782	<b>1.22</b>	(1.11-1.33)
	3	317	1.20	(0.99-1.45)	102	1.12	(0.83-1.51)	92	<b>1.65</b>	(1.20-2.27)	1047	<b>1.24</b>	(1.12-1.38)
	4+	265	<b>1.33</b>	(1.08-1.63)	84	1.17	(0.85-1.62)	79	<b>2.02</b>	(1.45-2.81)	748	<b>1.27</b>	(1.13-1.42)
P-value for trend test			<b>0.0047</b>			0.28			<b>0.0007</b>				<b>&lt; 0.0001</b>
Any cancer (excluding concordant cancer and cancer syndrome) <sup>6</sup>	0	326	ref	--	--	--	--	--	--	--	1063	ref	--
	1	639	1.14	(0.96-1.34)	--	--	--	--	--	--	2142	<b>1.15</b>	(1.05-1.25)
	2	532	1.19	(1.00-1.41)	--	--	--	--	--	--	1762	<b>1.21</b>	(1.11-1.33)
	3	320	<b>1.26</b>	(1.04-1.52)	--	--	--	--	--	--	995	<b>1.22</b>	(1.10-1.35)
	4+	241	<b>1.30</b>	(1.05-1.59)	--	--	--	--	--	--	689	<b>1.25</b>	(1.11-1.40)
P-value for trend test			<b>0.0059</b>			--			--				<b>&lt; 0.0001</b>
Concordant cancer	0	326	ref	--	114	ref	--	85	ref	--	1063	ref	--
	1	467	<b>1.61</b>	(1.37-1.88)	115	<b>1.59</b>	(1.22-2.07)	223	<b>2.70</b>	(2.04-3.59)	1849	<b>1.65</b>	(1.51-1.80)
	2	85	<b>2.41</b>	(1.85-3.13)	17	<b>2.45</b>	(1.46-4.12)	91	<b>6.53</b>	(4.67-9.13)	387	<b>2.25</b>	(1.97-2.58)
	3	19	<b>5.54</b>	(3.34-9.22)	1	1.73	(0.23-12.87)	17	<b>7.49</b>	(4.15-13.52)	71	<b>3.24</b>	(2.45-4.27)
	4+	4	<b>9.00</b>	(3.05-26.59)	0	--	--	6	<b>14.42</b>	(5.64-36.85)	12	<b>3.77</b>	(1.95-7.27)
P-value for trend test			<b>&lt; 0.0001</b>			<b>&lt; 0.0001</b>			<b>&lt; 0.0001</b>				<b>&lt; 0.0001</b>

1: N=Number of cancer cases among the index individuals;

2: RR=Relative risk;

3: CI=Confidence interval;

4: ref=Reference;

5: Family members who had the same cancer with the third generation cancer cases were excluded;

6: For colorectal cancer, cancer syndrome was endometrium cancer; for breast cancer, cancer syndrome was ovary cancer.



Smoking is a well-known environmental cause of familial clustering of cancer, and we thus assessed the familial risk of lung cancer and other tobacco related cancers when family members were diagnosed with any smoking related cancers (Table 4). Most of the RRs were significant and the trend tests were highly significant.

Table 4 Familial risks for tobacco related cancers among the third generation

Tobacco related cancer cases in the family	Lung cancer			Other tobacco related cancers			Tobacco related cancers		
	N <sup>1</sup>	RR <sup>2</sup>	95%CI <sup>3</sup>	N	RR	95%CI	N	RR	95%CI
0	471	ref <sup>4</sup>	--	1413	ref	--	1884	ref	--
1	197	<b>1.40</b>	(1.16-1.68)	473	1.12	(0.99-1.27)	670	<b>1.19</b>	(1.07-1.32)
2+	51	<b>1.78</b>	(1.29-2.46)	123	<b>1.46</b>	(1.16-1.82)	174	<b>1.54</b>	(1.27-1.86)
P-value for trend test			<b>&lt; 0.0001</b>	<b>0.0012</b>			<b>&lt; 0.0001</b>		

1: N=Number of cancer cases among the index individual;  
 2: RR=Relative risk;  
 3: CI=Confidence interval;  
 4: ref=Reference.

## DISCUSSION

In taking family histories and in advising concerned individuals from cancer families the physician frequently faces a problem if the pedigree shows many diverse cancers which do not fit into any of the known cancer syndromes. There is no unambiguous scientific evidence demonstrating the existence of an overall susceptibility to many cancers. Some supporting evidence is derived from cancer syndromes and known cancer predisposing genes which manifest cancers at many sites [6]. However, known cancer syndromes account for a small share of all cancers and the GWAS based approach on 13 different sporadic (i.e., not hereditary) cancers provided genetic evidence against genetic sharing between pairs of cancers [3]. Family studies from Utah, Iceland and Sweden have arrived at an essentially similar conclusion that pairwise analysis of cancer sites fails to support the hypothesis of an overall general susceptibility to cancer [7-10]. The present results contradict such conclusions as they provide population level evidence of predisposition to diverse common cancers. An important limitation of the present study is that the third generation had reached a maximal age of 65 years by the end of the follow-

up in year 2012 and most cancers were diagnosed at the 50s. As the median age of cancer diagnosis in Sweden is 70 years, a large proportion of the third generation had not entered the risk age for cancer.

The present approach is novel in considering families in 3 generations and, instead of a pair-wise analysis, it considers clustering of any cancers in the families. The approach was devised after considering the emerging knowledge of the germline genetic architecture of cancer, which is characterized by rare high-and medium-risk genes and numerous low-risk genes, detected by GWAS [15]. An illustrative point is the genetic architecture of prostate cancer, for which medium-risk genes account for a few percent while low-risk genes/loci account for 39 % of the familial clustering [16]. Thus, considering familial cancer in 3 generations and multiple relatives has the advantage that the threshold for penetrance is lowered.

The present data showed that the median individual in the third generation had 2 affected family members and his risk was 1.14 for any cancer. Furthermore, 7.0% had at least 5 affected relatives and their risk was about 1.46. To translate the latter figure into an absolute risk, the cumulative risk of cancer by 65 years (matching the maximal age in the present third generation) for combined sexes was 14.7 % in Sweden [17]; thus the RR of 1.46 would lead to an absolute risk of 21.5%. Looking at specific cancers, when having the same number of relatives affected with any cancer, the RR of prostate cancer was much higher than the overall RR (1.38 vs 1.08, 1.70 vs 1.14, 1.62 vs 1.19, 2.85 vs 1.28). Since 715 cases were diagnosed with prostate cancer, which accounted for a very small proportion of the third generation cancer patients (the total number of 41,106 cases), the higher RRs of prostate cancer did little contribution to the overall RRs. That could interpret familial risks for any cancer were not as high as prostate cancer; the risk of

prostate cancer risk was approximately equal (2.70 vs 2.85) if a man had 1 relative with prostate cancer or 4 or more relatives diagnosed with any cancer.

Although the present data do not provide direct insight into possible mechanisms, a large number of cancer predisposing genes are tumor suppressors [6]. A number of tumor suppressor genes are involved in DNA repair, guarding the integrity of the genome, or in other essential cellular processes, and it would be easily understandable that damage in such genes would promote cancers in many tissues; these processes have been coined as ‘hallmarks of cancer’ [18-21]. Furthermore GWASs have identified genomic locations which contribute to susceptibility of numerous cancers, including chromosome 8q24 next to the MYC gene and 5p next to the TERT gene [2, 22, 23]. However single nucleotide polymorphisms (SNPs) in these loci are largely specific to individual cancers but their clustering next to the important effector genes is thought to signal shared mechanisms. The complex regulation of these loci is not fully understood but they may contribute to shared susceptibility to multiple cancers. The recently detected ‘super enhancers’ are key regulatory elements, which promote oncogene transcription in many cancers and would provide another mechanistic rationale to the present findings [24, 25].

In conclusion, this nation-wide study on families spanning a century provided compelling evidence that there indeed is a general susceptibility to cancer. The results are weighted by common cancers – because they are more common they are more prominent in statistical analyses - and whether the overall susceptibility applies to all cancer needs to be resolved in future studies. The data provided herein provide tools for genetic counseling of “regular” patients with multiple cases of cancer in their family but lacking a clear-cut hereditary predisposition. Moreover, the present data help place cancer risk in high risk families into their correct context. Future

challenges include molecular identification of the underlying causes of familial accumulation as described here.

## **ACKNOWLEDGEMENT**

A.H. is Jane and Aatos Erkkö Professor of Oncology at the University of Helsinki.

## **CONFLICTS OF INTEREST DISCLOSURE**

Yes there are potential competing financial interests. A.H. is shareholder in Targovax ASA. A.H. is employee and shareholder in TILT Biotherapeutics Ltd.

## **FUNDING**

The study was supported by Deutsche Krebshilfe, Transcan by the German Federal Ministry of Education and Research and University of Helsinki.

## **AUTHOR CONTRIBUTIONS**

Study concept and design: K. Hemminki

Acquisition, analysis, or interpretation of data: Hongyao Yu, Christoph Frank, Jan Sundquist Kari Hemminki, Akseli Hemminki.

Drafting of the manuscript: Kari Hemminki, Hongyao Yu, Christoph Frank, Akseli Hemminki.

Critical revision of the manuscript for important intellectual content: Kari Hemminki, Akseli Hemminki, Hongyao Yu, Christoph Frank.

Statistical analysis: Hongyao Yu, Christoph Frank,

Obtained funding: Kari Hemminki, Jan Sundquist, Akseli Hemminki.

Final acceptance of the manuscript: Kari Hemminki, Hongyao Yu, Christoph Frank, Jan Sundquist, Akseli Hemminki.

## **REFERENCES**

1. Frank C, Fallah M, Sundquist J, Hemminki A, Hemminki K. Population Landscape of Familial Cancer. *Scientific reports* 2015;5:12891.
2. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. *Nat Rev Cancer* 2010;10:353-61.
3. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, Albanes

D, Amary MF, An SJ, Andersson U, Andriole G, Jr., Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W, Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF, Jr., Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R, 3rd, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD, 3rd, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, Kamineni A, Kane E, Kang CH, Karagas MR, Kelly RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Krickler A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Masala G, Mastrangelo G, Matsuo K, Maynadie M, McKay J, McKean-Cowdin R, Melbye M, Melin BS, Michaud DS, Mitsudomi T, Monnereau A, Montalvan R, Moore LE, Mortensen LM, Nieters A, North KE, Novak AJ, Oberg AL, Offit K, Oh IJ, Olson SH, Palli D, Pao W, Park IK, Park JY, Park KH, Patino-Garcia A, Pavanello S, Peeters PH, Perng RP, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Prokunina-Olsson L, Qian B, Qiao YL, Rais M, Riboli E, Riby J, Risch HA, Rizzato C, Rodabough R, Roman E, Roupert M, Ruder AM, Sanjose S, Scelo G, Schned A, Schumacher F, Schwartz K, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Setiawan VW, Severi G, Severson RK, Shanafelt TD, Shen H, Shen W, Shin MH, Shiraishi K, Shu XO, Siddiq A, Sierrasesumaga L, Sihoe AD, Skibola CF, Smith A, Smith MT, Southey MC, Spinelli JJ, Staines A, Stampfer M, Stern MC, Stevens VL, Stolzenberg-Solomon RS, Su J, Su WC, Sund M, Sung JS, Sung SW, Tan W, Tang W, Tardon A, Thomas D, Thompson CA, Tinker LF, Tirabosco R, Tjonneland A, Travis RC, Trichopoulos D, Tsai FY, Tsai YH, Tucker M, Turner J, Vajdic CM, Vermeulen RC, Villano DJ, Vineis P, Virtamo J, Visvanathan K, Wactawski-Wende J, Wang C, Wang CL, Wang JC, Wang J, Wei F, Weiderpass E, Weiner GJ, Weinstein S, Wentzensen N, White E, Witzig TE, Wolpin BM, Wong MP, Wu C, Wu G, Wu J, Wu T, Wu W, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Xu P, Yang PC, Yang TY, Ye Y, Yin Z, Yokota J, Yoon HI, Yu CJ, Yu H, Yu K, Yuan JM, Zelenetz A, Zeleniuch-Jacquotte A, Zhang XC, Zhang Y,


- Zhao X, Zhao Z, Zheng H, Zheng T, Zheng W, Zhou B, Zhu M, Zucca M, Boca SM, Cerhan JR, Ferri GM, Hartge P, Hsiung CA, Magnani C, Miligi L, Morton LM, Smedby KE, Teras LR, Vijai J, Wang SS, Brennan P, Caporaso NE, Hunter DJ, Kraft P, Rothman N, Silverman DT, Slager SL, Chanock SJ, Chatterjee N. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *Journal of the National Cancer Institute* 2015;107(12):dju279.
4. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. *N Engl J Med* 2003;348:919-32.
  5. Tavassoli F, Devilee P, editors. Tumours of the breast and female genital organs. Lyon: IARC Press, 2003.
  6. Rahman N. Realizing the promise of cancer predisposition genes. *Nature* 2014;505:302-8.
  7. Teerlink CC, Albright FS, Lins L, Cannon-Albright LA. A comprehensive survey of cancer risks in extended families. *Genetics in medicine : official journal of the American College of Medical Genetics* 2012;14(1):107-14.
  8. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. *Journal of the National Cancer Institute* 1994;86:1600-7.
  9. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, Gulcher JR, Bjornsson J, Kong A, Thorsteinsdottir U, Stefansson K. Cancer as a Complex Phenotype: Pattern of Cancer Distribution within and beyond the Nuclear Family. *PLoS Med* 2004;1:e65.
  10. Hemminki K, Sundquist J, Brandt A. Do discordant cancers share familial susceptibility? *Eur J Cancer* 2012;48:1200-7.
  11. Frank C, Fallah M, Ji J, Sundquist J, Hemminki K. The population impact of familial cancer, a major cause of cancer *Int J Cancer* 2014;134:1899-906.
  12. Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J. The Swedish Family-Cancer Database 2009: Prospects for histology-specific and immigrant studies. *Int J Cancer* 2010;126:2259-67.
  13. Frank C, Fallah M, T. C, Mai EK, Sundquist J, Forsti A, Hemminki K. Search for familial clustering of multiple myeloma with any cancer *Leukemia* 2016;30:627-32.
  14. Kianifard F, Gallo PP. Poisson regression analysis in clinical research. *Journal of biopharmaceutical statistics* 1995;5(1):115-29.
  15. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghousaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Roder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM,

- Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC, Kote-Jarai Z, Easton DF. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nature genetics* 2013;45(4):385-91, 91e1-2.
16. Amin AI, Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Vinuela A, Brown AA, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. *Human molecular genetics* 2015;24(19):5589-602.
  17. CentreforEpidemiology. Cancer incidence in Sweden 2012. Stockholm: The National Board of Health and Welfare, 2013.
  18. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. *Oncogene* 2004;23:6445-70.
  19. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004;10:789-99.
  20. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. *Science (New York, NY)* 2013;339(6127):1546-58.
  21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646-74.
  22. Sur I, Tuupanen S, Whittington T, Aaltonen LA, Taipale J. Lessons from functional analysis of genome-wide association studies. *Cancer research* 2013;73(14):4180-4.
  23. Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. *Current opinion in genetics & development* 2014;24:30-7.
  24. Niederriter AR, Varshney A, Parker SC, Martin DM. Super Enhancers in Cancers, Complex Disease, and Developmental Disorders. *Genes* 2015;6(4):1183-200.
  25. Seton-Rogers S. Transcription: Super-enhanced. *Nat Rev Cancer* 2015;15(1):4-5.

## **LEGENDS TO FIGURES**

Fig. 1. Birth year distribution of cancer patients in the 3 generations probands. The year of maximal number of cases is shown on top of each distribution.





First generation  
(N=468,549)

Second generation  
(N=367,642)

Third generation  
(N=48,730)